Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605498253 | ||
| 003 | CHVBK | ||
| 005 | 20210128100545.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00253-015-6776-x |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00253-015-6776-x | ||
| 245 | 0 | 0 | |a Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement? |h [Elektronische Daten] |c [Mariana Palma, Daniel Zamith-Miranda, Flaviano Martins, Fernando Bozza, Leonardo Nimrichter, Mônica Montero-Lomeli, Ernesto Marques Jr, Bruno Douradinha] |
| 520 | 3 | |a The probiotic yeast Saccharomyces cerevisiae var boulardii is widely used as a low cost and efficient adjuvant against gastrointestinal tract disorders such as inflammatory bowel disease and treatment of several types of diarrhea, both in humans and animals. S. boulardii exerts its protective mechanisms by binding and neutralizing enteric pathogens or their toxins, by reducing inflammation and by inducing the secretion of sIgA. Although several S. cerevisiae strains have proven probiotic potential in both humans and animals, only S. boulardii is currently licensed for use in humans. Recently, some researchers started using S. boulardii as heterologous protein expression systems. Combined with their probiotic activity, the use of these strains as prophylactic and therapeutic proteins carriers might result in a positive combined effort to fight specific diseases. Here, we provide an overview of the current use of S. cerevisiae strains as probiotics and their mechanisms of action. We also discuss their potential to produce molecules with biotherapeutic application and the advantages and hurdles of this approach. Finally, we suggest future directions and alternatives for which the combined effort of specific immunomodulatory effects of probiotic S. cerevisiae strains and ability to express desired foreign genes would find a practical application. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2015 | ||
| 690 | 7 | |a Probiotics |2 nationallicence | |
| 690 | 7 | |a Saccharomyces cerevisiae |2 nationallicence | |
| 690 | 7 | |a Saccharomyces cerevisiae var boulardii |2 nationallicence | |
| 690 | 7 | |a Mechanisms of action |2 nationallicence | |
| 690 | 7 | |a Expression of heterologous proteins |2 nationallicence | |
| 700 | 1 | |a Palma |D Mariana |u Laboratório de Dermatologia e Imunodeficiências, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil |4 aut | |
| 700 | 1 | |a Zamith-Miranda |D Daniel |u Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | |
| 700 | 1 | |a Martins |D Flaviano |u Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil |4 aut | |
| 700 | 1 | |a Bozza |D Fernando |u Instituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil |4 aut | |
| 700 | 1 | |a Nimrichter |D Leonardo |u Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | |
| 700 | 1 | |a Montero-Lomeli |D Mônica |u Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | |
| 700 | 1 | |a Marques Jr |D Ernesto |u University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA |4 aut | |
| 700 | 1 | |a Douradinha |D Bruno |u University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA |4 aut | |
| 773 | 0 | |t Applied Microbiology and Biotechnology |d Springer Berlin Heidelberg |g 99/16(2015-08-01), 6563-6570 |x 0175-7598 |q 99:16<6563 |1 2015 |2 99 |o 253 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00253-015-6776-x |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a review-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00253-015-6776-x |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Palma |D Mariana |u Laboratório de Dermatologia e Imunodeficiências, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Zamith-Miranda |D Daniel |u Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Martins |D Flaviano |u Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bozza |D Fernando |u Instituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nimrichter |D Leonardo |u Instituto de Microbiologia Paulo Goés, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Montero-Lomeli |D Mônica |u Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Marques Jr |D Ernesto |u University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Douradinha |D Bruno |u University of Pittsburgh Center for Vaccine Research, room 9052, 15213, Pittsburgh, PA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Applied Microbiology and Biotechnology |d Springer Berlin Heidelberg |g 99/16(2015-08-01), 6563-6570 |x 0175-7598 |q 99:16<6563 |1 2015 |2 99 |o 253 | ||